188 related articles for article (PubMed ID: 7850923)
1. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
7. CAI: effects on cytotoxic therapies in vitro and in vivo.
Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
[TBL] [Abstract][Full Text] [Related]
8. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
9. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Strawn LM; Kabbinavar F; Schwartz DP; Mann E; Shawver LK; Slamon DJ; Cherrington JM
Clin Cancer Res; 2000 Jul; 6(7):2931-40. PubMed ID: 10914743
[TBL] [Abstract][Full Text] [Related]
10. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
11. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
12. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
13. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
14. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
18. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
[TBL] [Abstract][Full Text] [Related]
19. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
20. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]